Clinical Trial Update: A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies [Phase 2]

View source ↗

Summary

Phase 2 trial in pediatric epilepsy evaluating TAK-935 as adjunctive therapy; completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dravet Syndrome
• Epilepsy
• Lennox-gastaut Syndrome

Drugs mentioned

• TAK-935 (OV935) (TAK-935)

Snippet

Sponsor: Takeda | Conditions: Epilepsy, Dravet Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2021-02-18